Response to: 'Response to: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: Post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg

Eric F. Morand, Teodora Trasieva, Anna Berglind, Gabor Illei, Raj Tummala

Research output: Contribution to journalLetterOtherpeer-review

1 Citation (Scopus)
Original languageEnglish
Number of pages1
JournalAnnals of the Rheumatic Diseases
Issue number11
Publication statusPublished - 1 Nov 2019


  • disease activity
  • systemic lupus erythematosus
  • treatment

Cite this